Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

BrainsWay reported strong earnings in Q2, with growth remaining strong and margins continuing to improve. Growth among enterprise accounts and internationally should ensure BrainsWay continues to perform well, provided that the macro environment remains stable. Neuronetics' decision to merge with Greenbrook TMS seems to support the strength of BrainsWay's business.

BrainsWay: Operating Leverage Driving Upside

Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Brainsway (BWAY) Might be Well Poised for a Surge

The mean of analysts' price targets for Brainsway (BWAY) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Brainsway (BWAY) Could Surge 72.29%: Read This Before Placing a Bet

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steve Lichtman - Oppenheimer Jeffery S.

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Generated Robust 28 % Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to $40 Million Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Brainsway (BWAY): Can Its 9.3% Jump Turn into More Strength?

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.

BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold

BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its broad market entry into Canada for the Company's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system through the signing of an exclusive multi-year distribution agreement with a specialty distributor serving both the acute hospital and non-acute healthcare spaces via a team of over 35 sales professionals and a portfolio of products across a range of clinical categories. The agreement includes minimum quantity orders which increase successively over several years, starting with 11 Deep TMS systems to be ordered in 2024.

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.

BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial

Aris Water Solution

MoneyLion

Small-cap stock investing is an interesting phenomenon, especially from a risk-return perspective. Many are under the illusion that small-cap stocks are risky by default.

Small-Cap Standouts: 3 Stocks Destined to Rule Their Industries

Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86 Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

The consensus price target hints at a 120.5% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Brainsway (BWAY) Could Rally 120.45%: Here's is How to Trade

BrainsWay reported strong Q1 results with profitability, positive cash flow, and strong growth. Market conditions have supposedly affected Neuronetics, but BrainsWay has not experienced similar problems. BrainsWay continues to expand its installed base and is exploring new indications for TMS treatment.

BrainsWay: Cash Flows Are Underappreciated

BrainsWay Ltd. (NASDAQ:BWAY ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Troy Williams – Investor Relations, Life Science Advisors Hadar Levy – Chief Executive Officer Ido Marom – Chief Financial Officer Conference Call Participants Jeff Cohen – Ladenburg Steve Lichtman – Oppenheimer Ram Selvaraju – H.C.

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Brainsway (BWAY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)

Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy

Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Crescent Point Energy

Genius Sports

Stereotaxis Inc

TransAlta

Taboola

TScan Therapeutics

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

CRH PLC

BWAY, WILYY and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 11, 2024.

Best Momentum Stocks to Buy for March 11th

Brookline Bancorp

InterDigital

Southside Bancshares

BWAY, WILLY, IDCC, BRKL and SBSI have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2024.

News for Brainsway Stock (BWAY)